P. Mease

发表

SAT0263 Biologic Therapy, Time to Low Disease Activity, and Effect of Mono Vs. Background Oral Dmard Therapy Among Psoriatic Arthritis Patients in a US Registry.

J. Greenberg, D. Collier, K. Saunders, 2013 .

OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials

G. Schett, R. Stevens, J. Gómez-Reino, 2014 .